

**Avicanna Inc.**

**Symbol:** TSXV: AVCN | OTCQX: AVCNF

**Market Cap:** 37M

**Sector:** Pharmaceuticals

**Purpose:** Raise Awareness / Open Market Buying

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medica and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars.

**Investor Bullet Points:**

* Commercial stage biopharmaceutical company with 314% Y-Y growth in revenues in over 20+ countries
* First pharmaceutical drug approval Q1 2024 for catastrophic epilepsy conditions
* Extensive pipeline of pharmaceutical drugs addressing dermatological, neurological and pain disorders
* Recently acquired medical cannabis by Shopper's drug mart

**Aras Azadian, Founder & CEO**

Utilizing his extensive senior management experience in both financial and bio-technology sectors, Aras founded Avicanna in 2016 with the vision of establishing a bio-pharmaceutical company with a strict focus on medical and pharmaceutical applications of cannabinoids. His expertise in corporate development coupled with his executive experience in the oncology industry have been integral to Avicanna’s thought leadership pertaining to R&D and clinical development. Since 2016 Aras has successfully led a team of executives, scientists and medical professionals across several countries with the vision of vertical integration and a strong company focus on quality controls, scientific vigour and competitive advantages. Aras holds a Bachelor of Economics degree from York University and an International Masters in Management degree from EADA Business School in Barcelona, Spain.